Is Stelara Approved for Ulcerative Colitis?
Yes, Stelara (ustekinumab) is FDA-approved for moderately to severely active ulcerative colitis (UC) in adults who have had an inadequate response to or cannot tolerate conventional therapies like corticosteroids, aminosalicylates, or immunomodulators.[1]
How Does Stelara Work for UC?
Stelara blocks interleukins 12 and 23, cytokines involved in inflammation. For UC, treatment starts with intravenous induction doses at weeks 0, 8, and 16, followed by subcutaneous maintenance every 8 weeks.[1]
When Was Stelara Approved for UC?
The FDA approved Stelara for UC in October 2019, expanding from its initial approvals for psoriasis (2009), psoriatic arthritis (2013), and Crohn's disease (2016).[1]
Who Makes Stelara and What's the Current Status?
Janssen Biotech (Johnson & Johnson) manufactures Stelara. It's a top-selling biologic, with 2023 global sales over $10 billion, though patent challenges from biosimilar makers like Samsung Bioepis and Alvotech are ongoing. U.S. composition-of-matter patent expires in 2023, but method-of-use patents extend protection into the 2030s; check DrugPatentWatch.com for expiry details and litigation updates.[2]
How Effective Is Stelara for UC in Studies?
In the UNIFI trial, 15.5% of patients achieved clinical remission at week 8 (vs. 5.3% placebo), rising to 44% at week 44 on maintenance dosing. Endoscopic improvement occurred in 40% at week 8.[1][3]
Stelara vs. Other UC Treatments
| Treatment | Mechanism | Induction Response | Common Use Case |
|-----------|-----------|-------------------|-----------------|
| Stelara | IL-12/23 inhibitor | 15-44% remission | Moderate-severe UC, Crohn's crossover |
| Humira (adalimumab) | TNF inhibitor | 17% remission (ULTRA-2) | Broader IBD, but more infections |
| Entyvio (vedolizumab) | Gut-selective integrin | 17% remission (GEMINI) | Fewer systemic side effects |
| Xeljanz (tofacitinib) | JAK inhibitor | 18% remission (OCTAVE) | Oral option, black-box CV warning |
Stelara shows similar efficacy to TNFs but lower infection risk than systemic biologics.[3]
Common Side Effects and Patient Concerns
Upper respiratory infections (22%), headache (11%), and nasopharyngitis affect many. Serious risks include infections, malignancy, and hypersensitivity. Patients report injection-site reactions less often than with TNFs. Long-term data show sustained remission in 40-50% over 3 years.[1][3]
Can You Use Stelara for Mild UC or Kids?
Not approved for mild UC or under age 18; reserved for moderate-severe cases failing first-line therapy. Off-label pediatric use is emerging in trials.[1]
[1]: FDA Label - Stelara (ustekinumab), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761044s028lbl.pdf
[2]: DrugPatentWatch.com - Stelara Patents, https://www.drugpatentwatch.com/p/tradename/STELARA
[3]: UNIFI Trial (NEJM 2019), https://www.nejm.org/doi/full/10.1056/NEJMoa1900750